Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Safety of two dose regimens of NXY-059 assessed in patients with stroke

May 4, 2001

Abaperidone advances to clinical testing based on favorable activity/side effect profile

May 4, 2001

New series synthesized at Arzneimittelwerk Dresden possess anticonvulsant, anxiolytic activity

May 3, 2001

Reduced beta-amyloid peptide levels observed with statin drugs

May 3, 2001

Preclinical models of ischemic stroke reveal neuroprotective activity of BMS-204352

May 3, 2001

GABA-A receptor ligands from MS&D useful for anxiety, epilepsy, cognition disorders

May 2, 2001

ORP150, a novel protein that contributes to neuronal resistance to ischemic stress

May 2, 2001

MetaPhore's enzyme mimetic shows potential as stroke treatment in animal model

May 2, 2001

Chrysamine G suppresses Abeta neurotoxicity and may be useful in Alzheimer's disease

May 2, 2001

New data demonstrate cognitive benefits with quetiapine in treatment-naive schizophrenia patients

May 2, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...